Mobile

Phase II trial of oral vinorelbine in combination with capecitabine and trastuzumab as first line therapy in women with previously untreated HER2 positive metastatic breast cancer

Update Il y a 4 ans
Reference: EUCTR2004-000748-26

Woman Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To evaluate the Overall Response Rate (ORR) of oral vinorelbine (Navelbine Oral) in combination with capecitabine (Xeloda) and i.v. trastuzumab (Herceptin) for HER2 positive patients.

Inclusion criteria

  • Treatment in women with previously untreated HER2 positive metastatic breast cancer

Links